<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079157</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000354502</org_study_id>
    <secondary_id>UPCC-11102</secondary_id>
    <nct_id>NCT00079157</nct_id>
  </id_info>
  <brief_title>Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer</brief_title>
  <official_title>Phase I Study Of Telomerase Peptide Vaccination For Patients With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Giving a&#xD;
      vaccine with Montanide ISA-51 and sargramostim may cause a stronger immune response and kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy&#xD;
      when given together with Montanide ISA-51 and sargramostim in treating patients with stage IV&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of telomerase: 540-548 peptide vaccine emulsified in Montanide&#xD;
           ISA-51 and sargramostim (GM-CSF) in patients with HLA-A2-expressing stage IV breast&#xD;
           cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the generation of human telomerase reverse transcriptase (hTERT)&#xD;
           peptide-specific vs cytomegalovirus peptide-specific cytotoxic T-lymphocyte (CTL)&#xD;
           immunity in patients treated with this regimen.&#xD;
&#xD;
        -  Correlate the dose level of this regimen with the generation of hTERT-specific CTL&#xD;
           immunity and the development of hTERT-specific autoimmunity in these patients.&#xD;
&#xD;
        -  Determine the tumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of the telomerase: 540-548 peptide and CMV 495&#xD;
      peptide portions of the vaccine.&#xD;
&#xD;
      Patients receive telomerase: 540-548 peptide and CMV 495 peptide (as an immunological&#xD;
      control) vaccine emulsified in Montanide ISA-51 subcutaneously (SC) followed by sargramostim&#xD;
      (GM-CSF) SC on day 1 of weeks 1, 3, 5, 7, 11, 15, 19, and 27 (for a total of 8 vaccinations).&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 5-8 patients receive escalating doses of telomerase: 540-548 peptide and CMV 495&#xD;
      peptide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 5 or 2 of 8 patients experience dose-limiting toxicity. A total&#xD;
      of 12 patients receive treatment at the MTD.&#xD;
&#xD;
      Patients are followed within 30 days and then at 6 and 12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 5-28 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>telomerase: 540-548 peptide vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of stage IV breast cancer&#xD;
&#xD;
          -  Failed at least 1 prior conventional therapy for metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable disease by clinical, radiographic, or laboratory assessment&#xD;
&#xD;
               -  Measurable lesions must be at least 1 dimension&#xD;
&#xD;
                    -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT&#xD;
                       scan&#xD;
&#xD;
               -  The following are not considered measurable:&#xD;
&#xD;
                    -  Pleural effusion&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Tumor markers&#xD;
&#xD;
          -  HLA-A2-expressing disease by human leukocyte antigen typing&#xD;
&#xD;
          -  No CNS metastases by contrast CT scan and/or MRI&#xD;
&#xD;
               -  No brain metastases within the past 4 years&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times ULN&#xD;
&#xD;
          -  Hepatitis B negative&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Human T-cell lymphotrophic virus-1 negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No major autoimmune disorder that would preclude study participation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             participation&#xD;
&#xD;
          -  No alcohol abuse or illicit drug use within the past 12 months&#xD;
&#xD;
          -  No clinically significant comorbid disease or other underlying condition that would&#xD;
             preclude study participation&#xD;
&#xD;
          -  No significant psychiatric disorder that would preclude giving informed consent or&#xD;
             complying with study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior allogeneic or autologous bone marrow or stem cell transplantation&#xD;
&#xD;
          -  More than 30 days since prior hematopoietic growth factors&#xD;
&#xD;
          -  More than 30 days since initiation of prior immunotherapy (e.g., trastuzumab&#xD;
             [Herceptin])&#xD;
&#xD;
          -  Concurrent immunotherapy (e.g., trastuzumab) allowed provided regimen was initiated&#xD;
             more than 30 days before study entry, disease is stable or progressive, and patient&#xD;
             plans to continue immunotherapy for the duration of study participation&#xD;
&#xD;
          -  No other concurrent hematopoietic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 30 days since prior glucocorticoids&#xD;
&#xD;
          -  More than 30 days since initiation of prior hormonal therapy (e.g., tamoxifen,&#xD;
             anastrozole, or letrozole)&#xD;
&#xD;
          -  Concurrent hormonal therapy (e.g., tamoxifen, anastrozole, or letrozole) allowed&#xD;
             provided regimen was initiated more than 30 days before study entry, disease is stable&#xD;
             or progressive, and patient plans to continue hormonal therapy for the duration of&#xD;
             study participation&#xD;
&#xD;
          -  No concurrent glucocorticoids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 30 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 14 days since prior anticoagulants (e.g., warfarin, heparin, or enoxaparin)&#xD;
&#xD;
               -  Low-dose anticoagulants to maintain IV catheter patency allowed&#xD;
&#xD;
          -  More than 30 days since prior immunosuppressive drugs&#xD;
&#xD;
          -  More than 30 days since prior experimental therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs&#xD;
&#xD;
          -  No other concurrent investigational products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Domchek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

